Clinical Trial Update: Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing the safety and immunogenicity of a Pfs25-Pfs25 conjugate malaria vaccine has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria
• Plasmodium Falciparum Malaria

Drugs mentioned

• Pfs25-Pfs25 conjugate vaccine (Pfs25-Pfs25 conjugate vaccine)

Snippet

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Conditions: Malaria, Malaria Vaccines | Phase 1 | Status: WITHDRAWN